On October 3, 2014 Kancera reported that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia (Press release Kancera, OCT 3, 2014, View Source;releaseID=932197 [SID:1234500830]). Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after 7 days of treatment in the examined organs of the animals. Deeper and more comprehensive analyzes are performed in order to verify the preliminary findings and to investigate the full effect of the treatment with KAN0439834 in the lymphatic system, which often suffers from infiltrating leukemia cells that are difficult to treat. Following this a decision can be made whether to select a first candidate drug in the ROR project.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conducted animal study is based on primary cancer cells from patients which adds clinical relevance to the model. Further studies during Q3 2014 have been performed to characterize the pharmaceutical properties of KAN0439834. Overall, the findings suggest that oral administration of KAN0439834 can provide a concentration of the substance in the blood sufficient to reach the desired effect against cancer cells.